Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period-Reference-Cited by-同舟云学术

Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period

Published:2020-05-07 Issue:6 Volume:99 Page:1257-1264
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Terpos Evangelos^ORCID,Ntanasis-Stathopoulos Ioannis^ORCID,Roussou Maria,Kanellias Nikolaos,Fotiou Despina^ORCID,Migkou Magdalini^ORCID,Eleutherakis-Papaiakovou Evangelos^ORCID,Gavriatopoulou Maria^ORCID,Kastritis Efstathios^ORCID,Dimopoulos Meletios A.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-020-04060-z.pdf

Reference44 articles.

1. Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F, Anderson KC (2017) Multiple myeloma. Nat Rev Dis Primers 3:17046. https://doi.org/10.1038/nrdp.2017.46

2. Castaneda-Avila MA, Ortiz-Ortiz KJ, Torres-Cintron CR, Birmann BM, Epstein MM (2019) Trends in cause of death among patients with multiple myeloma in Puerto Rico and the United States SEER population, 1987-2013. Int J Cancer 146:35–43. https://doi.org/10.1002/ijc.32232

3. Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J (2014) Curing myeloma at last: defining criteria and providing the evidence. Blood 124(20):3043–3051. https://doi.org/10.1182/blood-2014-07-552059

4. Verelst SGR, Blommestein HM, De Groot S, Gonzalez-McQuire S, DeCosta L, de Raad JB, Uyl-de Groot CA, Sonneveld P (2018) Long-term outcomes in patients with multiple myeloma. A retrospective analysis of the Dutch population-based HAematological registry for observational studies (PHAROS). HemaSphere 2(4):e45. https://doi.org/10.1097/HS9.0000000000000045

5. Jagannath S, Roy A, Kish J, Lunacsek O, Globe D, Eaddy M, Kuriakose ET, Willey J, Butler-Bird S, Siegel D (2016) Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices. Expert Rev Hematol 9(7):707–717. https://doi.org/10.1080/17474086.2016.1195254

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation;Blood Cancer Journal;2024-05-17

2. The Role of t(11;14) in Tailoring Treatment Decisions in Multiple Myeloma;Cancers;2023-12-13

3. Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2023-11

4. Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma;Frontiers in Oncology;2022-07-05

5. Recent therapeutic approaches in myeloma;Bone Cancer;2022